<code id='81B19A1ECF'></code><style id='81B19A1ECF'></style>
    • <acronym id='81B19A1ECF'></acronym>
      <center id='81B19A1ECF'><center id='81B19A1ECF'><tfoot id='81B19A1ECF'></tfoot></center><abbr id='81B19A1ECF'><dir id='81B19A1ECF'><tfoot id='81B19A1ECF'></tfoot><noframes id='81B19A1ECF'>

    • <optgroup id='81B19A1ECF'><strike id='81B19A1ECF'><sup id='81B19A1ECF'></sup></strike><code id='81B19A1ECF'></code></optgroup>
        1. <b id='81B19A1ECF'><label id='81B19A1ECF'><select id='81B19A1ECF'><dt id='81B19A1ECF'><span id='81B19A1ECF'></span></dt></select></label></b><u id='81B19A1ECF'></u>
          <i id='81B19A1ECF'><strike id='81B19A1ECF'><tt id='81B19A1ECF'><pre id='81B19A1ECF'></pre></tt></strike></i>

          fashion

          fashion

          author:fashion    Page View:77
          A Exterior of the new Ultragenyx biomanufacturing plant. -- biotech coverage from STAT
          Jonathan Wiggs /Globe Staff

          Ultragenyx said Thursday afternoon that its gene therapy for a rare liver ailment, glycogen disease type 1A, succeeded in a Phase 3 trial, setting up a potential approval.

          Patients with GSD1a, as the condition is often known, have a genetic mutation that prevents them from adequately maintaining blood sugar levels. Once considered fatal, GSD1a can now be controlled with regular doses of cornstarch. But if patients miss a dose, there can be significant, even life-threatening, complications.

          advertisement

          In the 49-person, randomized study, patients who received the Ultragenyx drug were able to take 41% less cornstarch after 48 weeks than they did at the start. Patients on placebo took only 10% less. The difference was statistically significant. Five patients were not included in the analysis, as three dropped out and the company didn’t have 48-week data from two.

          STAT+ Exclusive Story

          Already have an account? Log in

          STAT+

          This article is exclusive to STAT+ subscribers

          Unlock this article — plus daily coverage and analysis of the biotech sector — by subscribing to STAT+.

          Already have an account? Log in

          Already have an account? Log in

          Monthly

          $39

          Totals $468 per year

          $39/month Get Started

          Totals $468 per year

          Starter

          $30

          for 3 months, then $39/month

          $30 for 3 months Get Started

          Then $39/month

          Annual

          $399

          Save 15%

          $399/year Get Started

          Save 15%

          11+ Users

          Custom

          Savings start at 25%!

          Request A Quote Request A Quote

          Savings start at 25%!

          2-10 Users

          $300

          Annually per user

          $300/year Get Started

          $300 Annually per user

          View All Plans

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Wikipedia

          Walensky prepares to leave CDC — and Congress — behind
          Walensky prepares to leave CDC — and Congress — behind

          OutgoingCDCDirectorRochelleWalenskyJIMWATSON/AFPviaGettyImagesRochelleWalensky,theoutgoingdirectorof

          read more
          Florida health officials providing scant details on measles cases
          Florida health officials providing scant details on measles cases

          WithfewdetailsavailableaboutmeaslescasesinFlorida,peopleconsidering vacationstothestatewhowanttoavoi

          read more
          Cancer drug shortages should be causing more outrage
          Cancer drug shortages should be causing more outrage

          DrugshortagesareagrowingproblemintheU.S.,andashortageoflivesavingcancerdrugsinparticularhasreachedcr

          read more

          Sick patients collapsed waiting for care at Massachusetts hospital with known safety violations

          GoodSamaritanMedicalCenter,aMassachusettsHospital.SuzanneKreiter/GlobestaffStrugglingtobreathe,thepa